Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYROC: Hypofractionated Definitive Chemoradiotherapy for Esophageal Cancer
NCT07632079Phase 2Recruiting
- Sponsor
- University of Amsterdam
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in esophageal cancer and gastroesophageal junction cancer, sponsored by University of Amsterdam. Primary endpoint: Proportion of patients who complete all 20 fractions of radiotherapy and receive all 6 cycles of concurrent chemotherapy. Started Apr 2026; status: recruiting.
02
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07632079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632079.